Lighthouse Investment Partners LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Lighthouse Investment Partners LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the second quarter, Holdings Channel reports. The institutional investor bought 20,250 shares of the biotechnology company’s stock, valued at approximately $2,762,000.

Several other hedge funds have also made changes to their positions in the business. Private Ocean LLC acquired a new position in Ascendis Pharma A/S in the 1st quarter valued at about $36,000. GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the period. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter. Barometer Capital Management Inc. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $126,000. Finally, Searle & CO. purchased a new position in Ascendis Pharma A/S in the 2nd quarter valued at $205,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of analyst reports. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 price objective for the company. Citigroup increased their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Bank of America increased their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, TD Cowen decreased their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $195.00.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $144.62 on Friday. The stock has a fifty day moving average price of $134.39 and a 200 day moving average price of $136.61. The stock has a market cap of $8.42 billion, a PE ratio of -15.05 and a beta of 0.63. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. As a group, equities research analysts predict that Ascendis Pharma A/S will post -7.15 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.